Pasar al contenido principal

PEPTIDOS SINTETICOS COMO COMPONENTES CLAVE EN DIAGNOSTICO Y TERAPIA

PID2021-122216OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Structural Study of a Peptide Epitope Bearing Multiple Post-Translational Modifications in Rheumatoid Arthritis

  • Gómara, María José|||0000-0002-6906-4833
  • García-Moreno, Cristina
  • Bárcenas, Oriol|||0000-0002-8439-4005
  • Castellanos-Moreira, Raúl|||0000-0002-4104-4101
  • Sarmiento, Juan Camilo|||0000-0002-8426-7268
  • Crehuet, Ramon|||0000-0002-6687-382X
  • Pérez, Yolanda|||0000-0003-3767-5346
  • Sanmartí, Raimon|||0000-0002-8864-3806
  • Haro, Isabel|||0000-0001-8677-2340
Given the limited knowledge of the effect of post-translational modifications (PTMs) on protein structure, in this study we investigated whether introducing one-to-three RA-related PTMs into the α-fibrin (617-631) peptide influences the conformation and structure of the peptide antigen that could be responsible for the autoantibody recognition. Ten peptides containing a different number of PTMs within their primary structure were synthesized and their recognition by sera from RA patients was analyzed. The conformation of the peptides was studied by circular dichroism (CD) and the structure of the most relevant antigenic peptides was determined by nuclear magnetic resonance (NMR) and enhanced-sampling molecular dynamics (MD). Although peptides containing citrulline (Cit) showed a higher degree of binding to AMPAs than peptides containing only homocitrulline and/or acetyl-lysine, the latter were able to bind to AMPAs in sera that showed a small response to peptides with Cit, with the response being different depending on the position of each PTM. CD and NMR analyses indicated a series of half-turn conformations in the Lys620-Arg630 region. MD simulations generated a set of conformations compatible with the NMR NOEs. The effect of the PTMs was observed in intra-molecular contacts, hydrogen bonds and van der Waals interactions, generating more collapsed conformations. Differences in autoantibody reactivity between peptides bearing different PTMs within their primary structures are noted. Peptides with PTMs adopt different conformations than unmodified peptides, probably due to the lower net charge of peptides with multiple PTMs, which may explain their recognition by autoantibodies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study

  • Frade-Sosa, Beatriz
  • Ponce, Andrés
  • Ruiz-Ortiz, Estíbaliz
  • De Moner, Noemí
  • Gómara Elena, María José
  • Azuaga, Ana Belén
  • Sarmiento-Monroy, Juan C.
  • Morlà, Rosa
  • Ruiz-Esquide, Virginia
  • Macías, Laura
  • Sapena, Nuria
  • Tobalina, Lola
  • Ramirez, Julio
  • Cañete, Juan D.
  • Yague, Jordi
  • Auge, Josep M.
  • Gómez-Puerta, José A.
  • Viñas, Odette
  • Haro Villar, Isabel
  • Sanmarti, Raimon
This study assesses the accuracy of neutrophil activation markers, including neutrophil extracellular traps (NETs) and calprotectin, as biomarkers of disease activity in patients with established rheumatoid arthritis (RA). We also analyse the relationship between NETs and various types of therapies as well as their association with autoimmunity., This study was partially supported by a donation from Openbank through its “Open Solidario” program. This work was partially supported by a grant to I.H. (PID2021-122216OB-I00) funded by the Spanish Ministry of Economy, Industry and Competitiveness at the European Regional Development Fund. The journal’s Rapid Service Fee will be funded by the authors., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Chimeric Peptides Based on the Enolase Peptide Antigen (CEP-1) Bearing Three Post-Translational Modifications (Citrullination, Homocitrullination and Acetylation) for Determining the Diagnosis and Severity of Rheumatoid Arthritis

  • Gómara Elena, María José
  • Sarmiento-Monroy, Juan C.
  • Castellanos-Moreira, Raul
  • Gómez-Puerta, José A.
  • Sanmartí, Raimon
  • Haro Villar, Isabel
This article belongs to the Special Issue The Pathogenesis of Rheumatoid Arthritis—Breakthroughs in Molecular Mechanisms 2.0, With the aim of improving the uncertainties associated with the correct diagnosis of seronegative rheumatoid arthritis (RA) and identifying those at risk of developing interstitial lung disease (ILD), we have designed new peptide antigens bearing three post-translational modifications (PTMs) (citrulline, homocitrulline and acetyl-lysine) related to RA that could complement existing tests based on anti-citrullinated peptide/protein antibodies (ACPAs). Several chimeric peptides were synthesized and comparatively tested as antigens in ELISAs with two cohorts of sera: 178 RAs and 110 healthy blood donors. The results indicated that although chimeric peptides containing all three PTMs and vimentin and enolase domains do not significantly outperform existing ACPA tests in terms of sensitivity and specificity, they show potential to complement current assays, especially when detecting antibodies in some seronegative patients. Furthermore, the presence of these autoantibodies significantly identified patients with RA and ILD. We can conclude that the identification of specific autoantibody profiles using synthetic antigens containing peptide domains derived from proteins present in the human joint could help in the early detection of the risk of ILD in patients with RA and be useful for adapting follow-up strategies and guiding decisions during treatment, This research was funded by the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund (Grant No PID2021-122216OB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Engineering PSMA-targeted nanoparticles co-encapsulating mitoxantrone and indocyanine green for precise combinatory therapy in prostate cancer

  • Khalid, Hafiza Javeria
  • Khan, Sobia
  • Hussain, Danyaal
  • Obinyima, Amarachi
  • Pina, Clara
  • Walker, Harriet Rose
  • Pérez, Yolanda
  • Fox, Stuart
  • Elies, Jacobo
  • Gómara, María José
  • Haro Villar, Isabel
  • Ruiz, Amalia
Prostate cancer is the 2nd most common cancer in men worldwide. Chemotherapeutic treatment of prostate cancer with mitoxantrone (MTX) has limited efficacy due to severe side effects in which cardiotoxicity and myelosuppression are the two major causes of its dose-limiting toxicity. This study aimed to obtain a poly (lactic-co-glycolic acid) (PLGA) nanoparticle that can precisely deliver MTX to the prostate cancer cells overexpressing the Prostate-specific membrane antigen (PSMA) receptor-sparing healthy tissues and co-loading Indocyanine green (ICG) as a fluorescent photothermal/photodynamic agent for precise combinatory therapy in prostate cancer. The biocompatible polymer PLGA was covalently modified with the peptide of sequence (WQPDTAHHWATL) to actively target the PSMA receptor. Factors like the peptide-to-polymer ratio or the peptide's orientation during the polymer's chemical modification were investigated to enhance the active targeting of the nanoparticles (NPs). NPs were characterised using dynamic light scattering, scanning electron microscopy, and UV–vis spectroscopy to determine their morphological and colloidal properties and optimal MTX and ICG encapsulation efficiency. Quantitative FACS analysis of LNCaP and PC-3 cells incubated with Nile Red-labelled non-targeted PLGA or PLGA-PSMA targeted NPs was assessed to identify the best formulation that bound selectively to PSMA. The orientation of the peptide conjugated to the polymer, which has the C-terminal end of the peptide sequence accessible for interaction with the cell receptor, maximises the targeting capacity of the system. Photothermal experiments using 808 nm near-infrared laser irradiation were conducted, and cytotoxicity was assessed using the resazurin viability assay. Remarkably, our results confirmed the safety and efficacy of a targeted and activatable therapy using polymeric NPs functionalised with the peptide and co-loaded with MTX and ICG. This pioneer nanosystem opens new perspectives for exploring advanced targeted delivery in prostate cancer. It offers a straightforward methodology for functionalising drug delivery systems with bioactive peptides that can be applied to different types of cancer., A.R would like to thank The Royal Society for the Research Grant (RGS\R1\221399), the MRC Confidence in Concept grant (RM0039) and the University of Bradford for funding this research. This work was partially supported by a grant to I.H. (PID2021-122216OB-I00) funded by the Spanish Ministry of Economy, Industry and Competitiveness at the European Regional Development Fund. A.R, M.J.G. and I.H thank the network “Conexion Nanomedicina CSIC” for providing the opportunity to establish collaboration between our research groups. We also acknowledge Corbion Biomaterials (Gorinchem, The Netherlands) for the kind donation of PURASORB® polymers., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A lipid hydrogel to transport and release an anti-HIV-1 peptide into vaginal mucosa

  • Loza-Rodríguez, Noèlia
  • Millán-Sánchez, Aina
  • Benítez, Aleix
  • Pons Pons, Ramon
  • Gómara Elena, María José
  • Haro Villar, Isabel
  • Genescà, Meritxell
The cervicovaginal mucosa is a main portal of entry for the human immunodeficiency virus (HIV). Peptide antiretroviral therapy is a promising treatment to decrease the HIV infection rate, but yet it presents several weaknesses such as poor bioavailability, development of drug resistance and poor ability to reach the mucosal tissue with the effective concentration. In this work, an HIV inhibitor peptide (RE-E1P47) was encapsulated into a lipidic hydrogel (HG) to test its capacity to deliver the peptide to mucosa ex vivo and its pre-exposure prophylactic efficacy to inhibit or limit HIV infection. The proposed HG is made only with lipids and water and has a composition similar to the vaginal fluid that naturally covers the mucosa. Characterization studies with confocal microscopy, ATR-FTIR, SAXS and WAXS reveal that peptide incorporation does not alter the hydrogel's micro- and nanostructure. Permeation and diffusion tests confirm peptide delivery to the surface layers of the mucosal tissue without interaction or diffusion into a vaginal fluid simulant (VFS). Importantly, efficacy studies demonstrate a significant reduction in HIV infection rates of 60% after HG treatment. Thus, we highlight this material formulation as a strong candidate for mucosal topical application, particularly in the development of pre-exposure prophylaxis (PrEP) treatments against HIV-1., This work was supported by funds from the Spanish Ministry of Science and Innovation with Ayudas para contratos para la formación de doctores en empresas “Doctorados Industriales”, DIN2019-010777, Bicosome S. L., the Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project and PID2021-124848OB-I00 project. This work was also supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI20/00160), cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, from MCIN/AEI/10.13039/501100011033 and the European Union “Next Generation EU”/PRTR (CNS2022-135549 and PID2023-149204OB-I00), the Fundació La Marató TV3 (201814-10 FMTV3) and Gilead fellowships (GLD21/00049 and GLD23/00012) to M. G. M. J. G. and I. H. acknowledge the Grant PID2021-122216-OB-I00 received from the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A lipid hydrogel to transport and release an anti-HIV-1 peptide into vaginal mucosa

  • Loza i Rodríguez, Noèlia
  • Millán Sánchez, Aina
  • Pons, Ramon
  • Gómara, María José
  • Haro, Isabel
  • Benítez Martínez, Aleix
  • Genescà Ferrer, Meritxell
Lipid hydrogel; Peptide; Vaginal mucosa, Hidrogel lipídico; Péptido; Mucosa vaginal, Hidrogel lipídic; Pèptid; Mucosa vaginal, The cervicovaginal mucosa is a main portal of entry for the human immunodeficiency virus (HIV). Peptide antiretroviral therapy is a promising treatment to decrease the HIV infection rate, but yet it presents several weaknesses such as poor bioavailability, development of drug resistance and poor ability to reach the mucosal tissue with the effective concentration. In this work, an HIV inhibitor peptide (RE-E1P47) was encapsulated into a lipidic hydrogel (HG) to test its capacity to deliver the peptide to mucosa ex vivo and its pre-exposure prophylactic efficacy to inhibit or limit HIV infection. The proposed HG is made only with lipids and water and has a composition similar to the vaginal fluid that naturally covers the mucosa. Characterization studies with confocal microscopy, ATR-FTIR, SAXS and WAXS reveal that peptide incorporation does not alter the hydrogel's micro- and nanostructure. Permeation and diffusion tests confirm peptide delivery to the surface layers of the mucosal tissue without interaction or diffusion into a vaginal fluid simulant (VFS). Importantly, efficacy studies demonstrate a significant reduction in HIV infection rates of 60% after HG treatment. Thus, we highlight this material formulation as a strong candidate for mucosal topical application, particularly in the development of pre-exposure prophylaxis (PrEP) treatments against HIV-1., This work was supported by funds from the Spanish Ministry of Science and Innovation with Ayudas para contratos para la formación de doctores en empresas “Doctorados Industriales”, DIN2019-010777, Bicosome S. L., the Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project and PID2021-124848OB-I00 project. This work was also supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI20/00160), cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, from MCIN/AEI/10.13039/501100011033 and the European Union “Next Generation EU”/PRTR (CNS2022-135549 and PID2023-149204OB-I00), the Fundació La Marató TV3 (201814-10 FMTV3) and Gilead fellowships (GLD21/00049 and GLD23/00012) to M. G. M. J. G. and I. H. acknowledge the Grant PID2021-122216-OB-I00 received from the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A lipid hydrogel to transport and release an anti-HIV-1 peptide into vaginal mucosa

  • Loza i Rodríguez, Noèlia
  • Millán Sánchez, Aina
  • Pons, Ramon
  • Gómara, María José
  • Haro, Isabel
  • Benítez Martínez, Aleix
  • Genescà Ferrer, Meritxell
Lipid hydrogel; Peptide; Vaginal mucosa, Hidrogel lipídico; Péptido; Mucosa vaginal, Hidrogel lipídic; Pèptid; Mucosa vaginal, The cervicovaginal mucosa is a main portal of entry for the human immunodeficiency virus (HIV). Peptide antiretroviral therapy is a promising treatment to decrease the HIV infection rate, but yet it presents several weaknesses such as poor bioavailability, development of drug resistance and poor ability to reach the mucosal tissue with the effective concentration. In this work, an HIV inhibitor peptide (RE-E1P47) was encapsulated into a lipidic hydrogel (HG) to test its capacity to deliver the peptide to mucosa ex vivo and its pre-exposure prophylactic efficacy to inhibit or limit HIV infection. The proposed HG is made only with lipids and water and has a composition similar to the vaginal fluid that naturally covers the mucosa. Characterization studies with confocal microscopy, ATR-FTIR, SAXS and WAXS reveal that peptide incorporation does not alter the hydrogel's micro- and nanostructure. Permeation and diffusion tests confirm peptide delivery to the surface layers of the mucosal tissue without interaction or diffusion into a vaginal fluid simulant (VFS). Importantly, efficacy studies demonstrate a significant reduction in HIV infection rates of 60% after HG treatment. Thus, we highlight this material formulation as a strong candidate for mucosal topical application, particularly in the development of pre-exposure prophylaxis (PrEP) treatments against HIV-1., This work was supported by funds from the Spanish Ministry of Science and Innovation with Ayudas para contratos para la formación de doctores en empresas “Doctorados Industriales”, DIN2019-010777, Bicosome S. L., the Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project and PID2021-124848OB-I00 project. This work was also supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI20/00160), cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, from MCIN/AEI/10.13039/501100011033 and the European Union “Next Generation EU”/PRTR (CNS2022-135549 and PID2023-149204OB-I00), the Fundació La Marató TV3 (201814-10 FMTV3) and Gilead fellowships (GLD21/00049 and GLD23/00012) to M. G. M. J. G. and I. H. acknowledge the Grant PID2021-122216-OB-I00 received from the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund.